TREMFYA®在活动性银屑病关节炎（PsA）治疗中效果最好

On January 24, 2022, Janssen Pharmaceuticals, a division of Johnson & Johnson, announced a Network$ Analysis (NMA) using data from 33 Phase 3 randomized clinical trials (RCTs) to compare the first-in-class interleukin (IL)-23 inhibitor TREMFYA® (guselkumab) with all advanced therapies approved for active psoriatic arthritis (PsA).

Psoriatic arthritis is an inflammatory joint disease associated with psoriasis, characterized by a psoriatic rash accompanied by pain, swelling, tenderness, stiffness, and movement impairment in the joints and surrounding soft tissues.

The NMA concluded that among 23 treatment regimens (15 unique regimens, including IL-23 inhibitors such as TREMFYA and risankizumab, subcutaneous [SC] tumor necrosis factor inhibitors [TNFi], and Janus kinase inhibitors [JAKi]), TREMFYA had the highest skin clearance based on the Psoriasis (PsO) Area Severity Index (PASI) 90 response.

In terms of improvement in joint inflammation, the two dosing regimens of TREMFYA (100 mg every four weeks [q4w] and 100 mg every eight weeks [q8w]) were comparable to most other treatments in modified van der Heijde Sharp (vdH-S) scores, and TREMFYA was generally comparable to TNFi and American College of Rheumatology (ACR) 20 responses to most IL-17Ai. This analysis also confirmed the safety of TREMFYA in active PsA. TREMFYA is an injection approved by the U.S. Food and Drug Administration (FDA) and is administered at a dose of 100 mg at weeks 0 and 4, and then every 8 weeks.

"This comprehensive analytical approach allows for useful comparisons of existing psoriatic arthritis drugs," said Philip J. Mease, MD, of Swedish Medical Center/Providence St. Joseph's Health Center and the University of Washington in Seattle, Washington. "In my experience, comprehensive NMAs like this can help physicians discuss treatment options and effectiveness with their patients in their daily practice."

In the United States, Tremfya was first approved in July 2017 for the treatment of adults with moderate to severe plaque psoriasis. In July 2020, Tremfya was approved to treat adult patients with active PsA.

So far, Tremfya has been approved in many countries and regions around the world for the treatment of adult patients with moderate to severe plaque psoriasis.

References:

https://www.janssen.com/newly-published-network-meta-analysis-nma-found-tremfyar-guselkumab-ranked-highest-overall-level